Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Harnessing CRISPR/Cas9 to study group 2 innate lymphoid cells and their applications for immunotherapy
FY 2021-22
Summary
Harnessing CRISPR/Cas9 to study group 2 innate lymphoid cells and their applications for immunotherapyInnate Lymphoid Cells (ILCs) are a family of innate lymphocytes with important roles in maintaining tissue homeostasis, and work as part of cellular circuits to coordinate immune responses. Recent reports have identified a regulatory population of ILC2s that secrete interleukin (IL)-10 in addition to type 2 cytokines IL-4, IL-9 and IL-13 that are referred to as ILC2. These cells inhibit inflammatory response in different organs and are associated with improved clinical outcome in the context of allergen immunotherapy and transplantation. Our group has observed that the regulatory T-cell-associated transcription factor (TF) HELIOS is expressed by ILC2. We hypothesized that the protective effects observed in ILC2 could be driven by HELIOS expression. To test this hypothesis, we propose to establish a Crispr/Cas9 protocol for knockout in human ILCs. We will then use these knockouts to examine if HELIOS or IL-10 are required for human ILC2 immunoregulatory functions. We will address important questions, such as the impact of the knockout on cell proliferation and division, stability of gene knockout, and the impact of targeting these genes on expression of other ILC2 associated cytokines and TFs. Lastly, we aim to generate stable IL10-knockout ILC2 that can be used in a xenograft model of Graft-versus-Host-Disease (xenoGVHD) to assess whether IL-10 or HELIOS expression are required for ILC2 regulation of T cell responses and protection from xenoGVHD. Collectively, the proposed research would bring novel insights into factors regulating the phenotype and functions of ILC2, and generate a powerful tool for studying ILC biology and their clinical applications.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466657
Name
Audouze-Chaud Johanne
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing CRISPR/Cas9 to study group 2 innate lymphoid cells and their applications for immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Therapy; Crispr/Cas9; Flow Cytometry; Humanized Mouse Model; Il-10; Immune Regulation; Immunotherapy; Innate Lymphoid Cells; Lymphocyte Biology; Lymphocyte Development
Abstract
Harnessing CRISPR/Cas9 to study group 2 innate lymphoid cells and their applications for immunotherapyInnate Lymphoid Cells (ILCs) are a family of innate lymphocytes with important roles in maintaining tissue homeostasis, and work as part of cellular circuits to coordinate immune responses. Recent reports have identified a regulatory population of ILC2s that secrete interleukin (IL)-10 in addition to type 2 cytokines IL-4, IL-9 and IL-13 that are referred to as ILC2. These cells inhibit inflammatory response in different organs and are associated with improved clinical outcome in the context of allergen immunotherapy and transplantation. Our group has observed that the regulatory T-cell-associated transcription factor (TF) HELIOS is expressed by ILC2. We hypothesized that the protective effects observed in ILC2 could be driven by HELIOS expression. To test this hypothesis, we propose to establish a Crispr/Cas9 protocol for knockout in human ILCs. We will then use these knockouts to examine if HELIOS or IL-10 are required for human ILC2 immunoregulatory functions. We will address important questions, such as the impact of the knockout on cell proliferation and division, stability of gene knockout, and the impact of targeting these genes on expression of other ILC2 associated cytokines and TFs. Lastly, we aim to generate stable IL10-knockout ILC2 that can be used in a xenograft model of Graft-versus-Host-Disease (xenoGVHD) to assess whether IL-10 or HELIOS expression are required for ILC2 regulation of T cell responses and protection from xenoGVHD. Collectively, the proposed research would bring novel insights into factors regulating the phenotype and functions of ILC2, and generate a powerful tool for studying ILC biology and their clinical applications.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Audouze-Chaud, Johanne
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~